Journal of Microbiology, Immunology and Infection (Jun 2024)

Effect of early dexamethasone on outcomes of COVID-19: A quasi-experimental study using propensity score matching

  • Wang-Da Liu,
  • Jann-Tay Wang,
  • Ming-Chieh Shih,
  • Kai-Hsiang Chen,
  • Szu-Ting Huang,
  • Chun-Fu Huang,
  • Tien-Hao Chang,
  • Ming-Jui Tsai,
  • Po-Hsien Kuo,
  • Yi-Chen Yeh,
  • Wan-Chen Tsai,
  • Mei-Yan Pan,
  • Guei-Chi Li,
  • Yi-Jie Chen,
  • Kuan-Yin Lin,
  • Yu-Shan Huang,
  • Aristine Cheng,
  • Pao- Yu Chen,
  • Sung-Ching Pan,
  • Hsin-Yun Sun,
  • Shih-Chi Ku,
  • Sui-Yuan Chang,
  • Wang-Huei Sheng,
  • Chi-Tai Fang,
  • Chien-Ching Hung,
  • Yee-Chun Chen,
  • Yi-Lwun Ho,
  • Ming-Shiang Wu,
  • Shan-Chwen Chang

Journal volume & issue
Vol. 57, no. 3
pp. 414 – 425

Abstract

Read online

Background: The RECOVERY trial demonstrated that the use of dexamethasone is associated with a 36% lower 28-day mortality in hospitalized patients with COVID-19 on invasive mechanical ventilation. Nevertheless, the optimal timing to start dexamethasone remains uncertain. Methods: We conducted a quasi-experimental study at National Taiwan University Hospital (Taipei, Taiwan) using propensity score matching to simulate a randomized controlled trial to receive or not to receive early dexamethasone (6 mg/day) during the first 7 days following the onset of symptoms. Treatment was standard protocol-based, except for the timing to start dexamethasone, which was left to physicians’ decision. The primary outcome is 28-day mortality. Secondary outcomes include secondary infection within 60 days and fulfilling the criteria of de-isolation within 20 days. Results: A total of 377 patients with COVID-19 were enrolled. Early dexamethasone did not decrease 28-day mortality in all patients (adjusted odds ratio [aOR], 1.03; 95% confidence interval [CI], 0.97–1.10) or in patients who required O2 for severe/critical disease at admission (aOR, 1.05; 95%CI, 0.94–1.18); but is associated with a 24% increase in superinfection in all patients (aOR, 1.24; 95% CI, 1.12–1.37) and a 23% increase in superinfection in patients of O2 for several/critical disease at admission (aOR, 1.23; 95% CI, 1.02–1.47). Moreover, early dexamethasone is associated with a 42% increase in likelihood of delayed clearance of SARS-CoV-2 virus (adjusted hazard ratio, 1.42; 95% CI, 1.01–1.98). Conclusion: An early start of dexamethasone (within 7 days after the onset of symptoms) could be harmful to hospitalized patients with COVID-19.

Keywords